Table 1. Pediatric PCNSL cases reported... | American Society of Hematology

Table 1.

Pediatric PCNSL cases reported from 2006 to 2016

Reference	N	Median age (range)	Percentage immunocompromised	Histology				Treatment				Chemotherapy regimen	Outcome
Reference	N	Median age (range)	Percentage immunocompromised	DLBCL	ALCL	BL	Other	Chemo alone	Chemo + RT	Resection before treatment	Other	Chemotherapy regimen	Outcome
Abla et al, 2006³	12	7.5 y (4-17 y)	33	42%	33%	8%	17%	83%	17%	8%	0	Ara-C and/or MTX based: 92%	9/12 patients alive
Abla et al, 2006³	12	7.5 y (4-17 y)	33	42%	33%	8%	17%	83%	17%	8%	0	Palliative hydroxyurea: 8%	5-y EFS 70%*
Abla et al, 2011⁵	29	14 y (2-21 y)	10	69%	17%	7%	7%	62%	31%	31%	7%	MTX-based: 93%	3-y OS 82%
Abla et al, 2011⁵	29	14 y (2-21 y)	10	69%	17%	7%	7%	62%	31%	31%	7%	Non-MTX based: 7%	3-y OS 82%
Yoon et al, 2012⁸	6	10 y (23 mo-13 y)	0	50%	0	33%	17%	100%	0	0	0	LMB96: 83%	5-y OS 83%
Yoon et al, 2012⁸	6	10 y (23 mo-13 y)	0	50%	0	33%	17%	100%	0	0	0	CCG106B: 17%	5-y OS 83%
Thorer et al, 2014⁷	17	13 y (1-17 y)	30	41%	29%	6%	24%	71%	29%	0	0	NHL-BFM90,	3-y OS 63% (whole cohort)
												NHL-BFM95, or	3-y OS 92% (immune competent)
												B-NHL BFM04	3-y OS 92% (immune competent)
O’Suoji et al, 2016⁶	5	13 y (6-16 y)	20	40%	40%	0	20%	NR	NR	NR	NR	NR	EFS and OS 100% with median follow-up 2.1 y

Reference	N	Median age (range)	Percentage immunocompromised	Histology				Treatment				Chemotherapy regimen	Outcome
Reference	N	Median age (range)	Percentage immunocompromised	DLBCL	ALCL	BL	Other	Chemo alone	Chemo + RT	Resection before treatment	Other	Chemotherapy regimen	Outcome
Abla et al, 2006³	12	7.5 y (4-17 y)	33	42%	33%	8%	17%	83%	17%	8%	0	Ara-C and/or MTX based: 92%	9/12 patients alive
Abla et al, 2006³	12	7.5 y (4-17 y)	33	42%	33%	8%	17%	83%	17%	8%	0	Palliative hydroxyurea: 8%	5-y EFS 70%*
Abla et al, 2011⁵	29	14 y (2-21 y)	10	69%	17%	7%	7%	62%	31%	31%	7%	MTX-based: 93%	3-y OS 82%
Abla et al, 2011⁵	29	14 y (2-21 y)	10	69%	17%	7%	7%	62%	31%	31%	7%	Non-MTX based: 7%	3-y OS 82%
Yoon et al, 2012⁸	6	10 y (23 mo-13 y)	0	50%	0	33%	17%	100%	0	0	0	LMB96: 83%	5-y OS 83%
Yoon et al, 2012⁸	6	10 y (23 mo-13 y)	0	50%	0	33%	17%	100%	0	0	0	CCG106B: 17%	5-y OS 83%
Thorer et al, 2014⁷	17	13 y (1-17 y)	30	41%	29%	6%	24%	71%	29%	0	0	NHL-BFM90,	3-y OS 63% (whole cohort)
												NHL-BFM95, or	3-y OS 92% (immune competent)
												B-NHL BFM04	3-y OS 92% (immune competent)
O’Suoji et al, 2016⁶	5	13 y (6-16 y)	20	40%	40%	0	20%	NR	NR	NR	NR	NR	EFS and OS 100% with median follow-up 2.1 y

Among patients treated with chemotherapy alone.

NR, not reported.